Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 6.05 million ordinary shares on November 25, 2025, as part of its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Group 1 - The company will issue 6.05 million ordinary shares [1]

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | 於下列日期開始時的結存(註1) | | 2025年11月19日 | | 4,107,272,633 | | 0 | | 4,107,272,633 | | 1). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | | | 4,000 | 0.0001 % | HKD | 1.67 ...

Core Viewpoint - The launch of the Hang Seng Biotechnology Index futures on November 28 is expected to provide investors with new risk hedging tools and enhance liquidity in the biotechnology sector [1] Group 1: Index and Market Overview - The Hang Seng Biotechnology Index was launched by Hang Seng Indexes Company in 2019 to reflect the overall performance of the biotechnology sector in the Hong Kong stock market [1] - The index currently includes notable companies such as Innovent Biologics, BeiGene, WuXi Biologics, CanSino Biologics, and 3SBio, covering sub-sectors like CXO and innovative drugs [1] Group 2: Market Trends and Expectations - The introduction of the index futures is anticipated to attract foreign capital back to the biotechnology sector amid a global liquidity easing cycle initiated by the Federal Reserve's interest rate cuts [1] - The continuous inflow of southbound funds is expected to create a resonance effect, further boosting the biotechnology sector in the Hong Kong market [1]

Group 1: Top Net Buy Companies - Xiaomi Group-W (1810.HK) had a net buy amount of 40.31 billion CNY with a holding change of 105,862,338 shares[9] - China National Offshore Oil Corporation (0883.HK) saw a net buy of 31.73 billion CNY with a holding change of 147,299,898 shares[9] - Industrial and Commercial Bank of China (1398.HK) recorded a net buy of 20.45 billion CNY with a holding change of 319,540,224 shares[9] Group 2: Top Net Sell Companies - Alibaba Group-W (9988.HK) experienced the highest net sell of -63.35 billion CNY with a holding change of -42,921,071 shares[10] - Tracker Fund of Hong Kong (2800.HK) had a net sell of -8.63 billion CNY with a holding change of -34,043,500 shares[10] - Meituan-W (3690.HK) saw a net sell of -7.21 billion CNY with a holding change of -7,546,076 shares[10] Group 3: Industry Distribution of Net Buy/Sell - The financial sector had significant net buying activity, contributing positively to the overall market[14] - The energy sector also showed strong net buying, particularly with companies like China National Offshore Oil Corporation[14] - The consumer discretionary sector faced notable net selling, primarily driven by Alibaba Group-W and Meituan-W[14]

Core Viewpoint - Chinese concept stocks experienced a collective surge, with the Nasdaq China Golden Dragon Index rising by 2.82% on November 24, 2023, driven by expectations of a potential interest rate cut by the Federal Reserve in December [1] Group 1: Market Performance - Major Chinese stocks saw significant gains: Baidu increased by over 7%, Bilibili by over 6%, Alibaba by over 5%, NetEase by over 4%, and NIO by over 3% [1] - The probability of a 25 basis point rate cut by the Federal Reserve in December rose to 82.9%, a substantial increase from previous forecasts [1] Group 2: Industry Outlook - CITIC Securities indicated that with macroeconomic improvements, Hong Kong stocks are expected to transition from "earnings recovery" to "revenue expansion," creating a sustainable upward trend in both revenue and profit [1] - The Hong Kong stock market is poised to benefit from the outflow of liquidity from domestic and international markets, alongside the ongoing AI narrative, as more high-quality leading A-share companies list in Hong Kong [1] Group 3: Index and ETF Information - The National Index Hong Kong Stock Connect Technology Index selects 30 leading technology companies based on market capitalization, R&D investment, and revenue growth, including Tencent, Alibaba, Xiaomi, Meituan, SMIC, and BYD [5][8] - The index requires constituent stocks to have a compound revenue growth rate exceeding 10% over the past two years or an R&D expense ratio above 5%, balancing scale and growth potential [5] - The latest valuation of the Hong Kong Technology Index is 22.92 times PE, positioned at the 15th percentile since its inception [12] Group 4: Key Constituents - The top five constituents of the Hong Kong Stock Connect Technology Index include Alibaba (18.03%), Tencent (15.27%), Xiaomi (11.83%), Meituan (9.10%), and SMIC (6.80%) [9] - The index has a high concentration, with the top five stocks accounting for over 61% and the top ten nearly 80% of the total weight [7] Group 5: Future Market Sentiment - Huatai Securities noted that the sentiment in the Hong Kong stock market remains pessimistic, indicating a balanced risk profile, suggesting that investors may gradually build positions [20] - CITIC Securities anticipates that the "money-making effect" in the Chinese stock market will continue, with domestic investors likely to increase their allocation to Hong Kong stocks due to current underexposure [20]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.44%, Green Power Environmental (01330) at 69.47%, and Da Zhong Public Utilities (01635) at 69.41% [1][2] - Alibaba-W (09988), Tracker Fund of Hong Kong (02800), and Xiaomi Group-W (01810) saw the largest increases in holding amounts over the last five trading days, with increases of +6.391 billion, +5.358 billion, and +2.533 billion respectively [1][2] - WuXi Biologics (02269), China Mobile (00941), and Crystal International (02228) experienced the largest decreases in holding amounts, with reductions of -612 million, -485 million, and -473 million respectively [1][3] Hong Kong Stock Connect Holding Ratios - China Telecom (00728) holds 10.054 billion shares, representing 72.44% of its total [2] - Green Power Environmental (01330) holds 281 million shares, representing 69.47% of its total [2] - Da Zhong Public Utilities (01635) holds 370 million shares, representing 69.41% of its total [2] Recent Increases in Holdings - Alibaba-W (09988) saw an increase of +6.391 billion in holding amount, with a change of +41.368 million shares [2] - Tracker Fund of Hong Kong (02800) increased by +5.358 billion, with a change of +207.532 million shares [2] - Xiaomi Group-W (01810) increased by +2.533 billion, with a change of +65.508 million shares [2] Recent Decreases in Holdings - WuXi Biologics (02269) decreased by -612 million in holding amount, with a change of -19.247 million shares [3] - China Mobile (00941) decreased by -485 million, with a change of -5.542 million shares [3] - Crystal International (02228) decreased by -473 million, with a change of -46.770 million shares [3]

Core Insights - The article highlights the net inflow and outflow of funds in the Hong Kong stock market, with specific focus on the top performers and laggards in terms of capital movement [1][2][3] Fund Inflows - The top three stocks with the highest net inflow are: - 盈富基金 (02800) with a net inflow of 74.33 billion, representing a 24.09% increase in capital [2] - 恒生中国企业 (02828) with a net inflow of 19.17 billion, showing a 29.84% increase [2] - 南方恒生科技 (03033) with a net inflow of 14.88 billion, reflecting a 14.32% increase [2] Fund Outflows - The top three stocks with the highest net outflow are: - 小米集团-W (01810) with a net outflow of -6.11 billion, indicating a -4.66% decrease [2] - 泡泡玛特 (09992) with a net outflow of -2.74 billion, showing an -8.07% decrease [2] - 兖矿能源 (01171) with a net outflow of -1.84 billion, reflecting a -43.34% decrease [2] Net Inflow Ratios - The stocks with the highest net inflow ratios are: - 南方港美科技 (03442) at 75.22% with a net inflow of 711.95 million [2] - 工银南方中国 (03167) at 75.00% with a net inflow of 10.4 million [2] - 保诚 (02378) at 64.37% with a net inflow of 539.33 million [2] Net Outflow Ratios - The stocks with the highest net outflow ratios are: - 中国春来 (01969) at -67.51% with a net outflow of -146.76 million [3] - 丘钛科技 (01478) at -58.59% with a net outflow of -969.83 million [3] - 中国东方教育 (00667) at -56.10% with a net outflow of -1830.56 million [3]

Core Viewpoint - Morgan Stanley's research report indicates that WuXi AppTec's valuation levels are becoming more attractive amid a stable fundamental backdrop, with a particular focus on WuXi AppTec as a preferred stock due to its robust performance and growth potential [1] Group 1: Company Performance - WuXi AppTec has raised its earnings guidance and is undergoing significant capacity expansion, particularly in the next-generation GLP-1 sector [1] - The earnings forecasts for WuXi AppTec for the years 2025 to 2027 have been increased by 3% to 4% [1] - WuXi Biologics' earnings estimates for 2025 to 2027 have been raised by 6% to 13% [1] - WuXi AppTec's subsidiary, WuXi STA, has seen its earnings projections adjusted upward by 7% to 8% [1] Group 2: Growth Projections - The compound annual growth rates (CAGR) for the three companies from 2024 to 2027 are projected to be 24%, 23%, and 37% respectively [1]

Group 1 - Morgan Stanley's research report indicates that WuXi AppTec's valuation levels are attractive amid a stable fundamental backdrop, with a particular focus on WuXi Biologics [1] - The report highlights that WuXi Biologics has raised its earnings guidance and is undergoing significant capacity expansion, with high participation in the next-generation GLP-1 sector [1] - The firm has upgraded earnings forecasts for WuXi Biologics for 2025 to 2027 by 6% to 13%, and for WuXi AppTec by 3% to 4%, designating WuXi AppTec as a top pick [1] Group 2 - The compound annual growth rates for the three companies from 2024 to 2027 are projected at 24%, 23%, and 37% respectively [1] - Other major banks, including Oriental Securities and Goldman Sachs, have also maintained positive ratings on WuXi AppTec and WuXi Biologics, citing strong performance and robust customer demand [2] - Goldman Sachs set a target price of HKD 63.3 for WuXi AppTec, reflecting confidence in the company's order momentum and customer demand [2]

该行提到，药明康德(603259.SH)A股为投资者带来理想的买入机会，上调公司2025至27年盈测3至4%， 并列为首选股;将药明生物(02269)2025至27年盈测调升6至13%;升药明合联(02268)盈测7至8%。综合而 言，三间公司2024至27年的盈利复合年增长率分别为24%、23%及37%。 智通财经APP获悉，摩根士丹利发布研报称，中国医疗保健股自9月中旬起被持续抛售，投资者正在获 利了结，并等待明年业绩发展的讯号。该行指出，当中药明系在基本面持续稳健的背景下，估值水平更 具吸引力。大摩最看好药明康德(02359)，因此该公司不仅上调业绩指引，更进行大规模产能扩张，且 在下一代GLP-1领域参与度高。 ...